SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$10.33
−27.72%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.51
- Revenue estimate
- $95.1M
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- -$0.55
- EPS estimate
- -$0.50
- Revenue actual
- $83.3M
- Revenue estimate
- $81.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.8%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $36
- PT range
- $33 – $40
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | -$0.50 | -$0.55 | Miss -9.11% | $83.3M |
| Aug 4, 2026 | -$0.45 | -$0.55 | Miss -22.86% | $72.8M |
| Apr 30, 2026 | -$0.59 | -$0.48 | Beat 18.64% | $64.9M |
| Mar 3, 2025 | -$1.08 | -$1.10 | Miss -1.85% | $7.7M |
| Aug 1, 2024 | -$0.91 | -$0.80 | Beat 12.09% | $3.5M |
| May 8, 2024 | -$0.96 | -$0.85 | Beat 11.46% | — |
| Feb 27, 2024 | -$0.99 | -$1.00 | Miss -1.01% | $536.0K |
| Nov 2, 2023 | -$0.80 | -$0.73 | Beat 8.75% | — |
| Aug 3, 2023 | -$0.73 | -$0.64 | Beat 12.33% | — |
| Feb 28, 2023 | -$0.64 | -$0.62 | Beat 3.13% | — |
| Nov 3, 2022 | -$0.65 | -$0.58 | Beat 10.77% | — |
| Mar 1, 2022 | $0.28 | $1.81 | Beat 546.43% | $126.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027